Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Under their 2015 research agreement giving Vertex Pharmaceuticals Inc. option rights on up to six candidates, the Cambridge, Mass.-based...








